We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Aspirin Found to Decrease Stomach Cancer Risk

By LabMedica International staff writers
Posted on 03 Mar 2009
Aspirin users could be 36% less likely to get a type of stomach cancer, according to recent research.

In a study of over 300,000 people, the researchers found that people who had taken aspirin at least once in the previous year were considerably less likely to get noncardia gastric cancer (cancer of the middle or lower parts of the stomach). More...
There was also a 32% reduction for the same type of stomach cancer in individuals who used other types of nonsteroidal antiinflammatory drugs (NSAIDs).

In contrast to results of previous studies, the researchers found that aspirin does not protect against esophageal cancer and cardia gastric cancer, which is cancer of the top of the stomach. Taking aspirin regularly has been found to cut the risk of bowel cancer, but it is not currently recommended because side effects could include bleeding within the abdomen.

Now, scientists believe that placebo-controlled trials, which would evaluate risks and benefits, should be conducted to see if NSAIDs could be used to protect against stomach and esophageal cancers. Five-year survival rates for these cancers are 15 and 8% in the United Kingdom, respectively, so research in how to prevent the disease is important.

Study author Dr. Christian Abnet, based at the U.S. National Cancer Institute (NCI; Rockville, MD, USA), said, "We found that the risk of non-cardia stomach cancer was lower in people who had taken aspirin, and this risk lowered the more regularly they took it. Interestingly, our results didn't show a significant cut in the risk of esophageal or cardia stomach cancer, so it's important that we continue to review data that suggest otherwise. The number of people who survive at least five years following a diagnosis of stomach or esophageal cancer is low, so it's important to increase our understanding of ways to prevent the disease and to investigate aspirin as a possible preventative drug.”

The rate of non-cardia stomach cancer calculated in this study was 7 per 100,000 person-years for aspirin users, compared with 11 per 100,000 person-years for non-users. The figures were calculated from a study of more than 311,000 people in the United States and an analysis of 17 published studies on the topic.

Each year in the United Kingdom, approximately 8,000 people are diagnosed with stomach cancer, and about 5,250 people die from the disease. Dr. Lesley Walker, director of cancer information at Cancer Research UK (London), commented, "It's far too early to recommend that people take aspirin to protect themselves from these cancers. In cancers where survival is low, understanding how to prevent the disease is crucial, but more research is needed to discover how side effects can be balanced with the benefits. Cancer Research UK would urge people to speak to their doctor before taking aspirin regularly.”

The study was published in the February 2009 issue of the British Journal of Cancer (BJC).

Related Links:

National Cancer Institute




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.